RuxolitinibAn inhibitor of JAK1, JAK2, and JAK3

Ruxolitinib (CAS 941678-49-5)

Ruxolitinib | CAS 941678-49-5 is rated 5.0 out of 5 by 1.
  • y_2019, m_11, d_19, h_17
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.3-b1
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_364729, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 72ms
  • REVIEWS, PRODUCT
5
1
4
0
3
0
2
0
1
0
Synonym: (3R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Application: An inhibitor of JAK1, JAK2, and JAK3
CAS Number: 941678-49-5
Purity: ≥98%
Molecular Weight: 306.37
Molecular Formula: C17H18N6
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

Ruxolitinib (INCB018424) is a JAK inhibitor of JAK1 (IC50 = 2.7 nM), JAK2 (IC50 = 4.5 nM), and JAK3 (IC50 = 322 nM). JAKs, or Janus-associated kinases, are tyrosine kinases found in the cytoplasm that are known to activate the signaling of certain growth factor receptors and cytokines.

Appearance :
Powder
Physical State :
Solid
Solubility :
Soluble in DMSO (61 mg/ml at 25 °C), ethanol (15 mg/ml) with warming, DMF (~5 mg/ml), water (<1 mg/ml at 25 °C), and methanol.
Storage :
Store at -20° C
Melting Point :
86-89° C
Boiling Point :
~592.6° C at 760 (Predicted)
Density :
~1.4 g/cm3 (Predicted)
Refractive Index :
n20D 1.75 (Predicted)
Optical Activity :
α20D -8.0°, c = 0.3 in methanol
IC50 :
JAK1: IC50 = 0.8 nM (human); JAK2: IC50 = 2.8 nM (human); JAK3: IC50 = 10.7 nM (human); Tyk 2: IC50 = 19 nM (human); JAK3/JAK1: IC50 = 23 nM (human)
Ki Data :
JAK1: Ki= 0.09 nM (human); JAK2: Ki= 0.1 nM (human); Tyk 2: Ki= 0.5 nM (human); JAK3: Ki= 3.2 nM (human)
pK Values :
pKa: 11.63 (Predicted), pKb: 3.67 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
PubChem CID :
25126798
MDL Number :
MFCD12031592
SMILES :
C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

Ruxolitinib  Product Citations

See how others have used Ruxolitinib. Click on the entry to view the PubMed entry .

Citations 1 to 7 of 7 total

PMID: # 31391303  2019. Proc. Natl. Acad. Sci. U.S.A. 116: 17399-17408.

PMID: # 30247637  2018. Mol. Hum. Reprod. 24: 533-542.

PMID: # 30348790  2018. Eur. J. Pharmacol. 834: 65-76.

PMID: # 29907868  Ménoret, A.|Buturla, JA.|Xu, MM.|Svedova, J.|Kumar, S.|Rathinam, VAK.|Vella, AT.| et al. 2018. Mucosal Immunol. 11: 1398-1407.

PMID: # 30012499  Mesbahi, Y.|Zekri, A.|Ghaffari, SH.|Tabatabaie, PS.|Ahmadian, S.|Ghavamzadeh, A.| et al. 2018. Eur. J. Pharmacol. 834: 65-76.

PMID: # 27035543  Jinushi, M. et al. 2016. Viral immunology. 29: 296-306.

PMID: # 26573834  Tsurutani, N. et al. 2016. Journal of immunology (Baltimore, Md. : 1950). 196: 124-34.

Citations 1 to 7 of 7 total

Puo essere utilizzato per malati di policitemia vera?

Asked by: francesco
Grazie per la domanda. Tutti i reagenti chimici e gli anticorpi offerti dalla Santa Cruz Biotechnology, Inc. sono forniti solo per ricerca di laboratorio in vitro (in-vitro RUO). I prodotti non sono destinati ad uso diagnostico o terapeutico e non devono essere utilizzati su animali o persone. Thank you for your question. All chemicals and antibodies offered by Santa Cruz Biotechnology, Inc. are supplied for laboratory in-vitro research use only (in-vitro RUO). The products are not intended for diagnostic or therapeutic use and must not be applied to animals or humans.
Answered by: Technical Support Europe
Date published: 2016-10-11
  • y_2019, m_11, d_19, h_17CST
  • bvseo_bulk, prod_bvqa, vn_bulk_3.0.3-b1
  • cp_1, bvpage1
  • co_hasquestionsanswers, tq_1
  • loc_en_US, sid_364729, prod, sort_[SortEntry(order=LAST_APPROVED_ANSWER_SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 98ms
  • QUESTIONS, PRODUCT
Rated 5 out of 5 by from Alimam et al Alimam et al. (PubMed ID 26343888) used Ruxolitinib to inhibit JAK1/2 in low-risk myelofibrosis patients. -SCBT Publication Review
Date published: 2015-02-27
  • y_2019, m_11, d_19, h_17
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.3-b1
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_364729, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 85ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.